Stories about Metabolic disorder

Subscribe to topic

Subscribe to Metabolic disorder

09.01.2020 – 13:00
Debiopharm International SA
Novadiscovery raises series A financing to scale its in silico clinical trial platform - Debiopharm leads the round with EUR 5 million
Lausanne (ots) - - Novadiscovery pioneers the use of in silico clinical trials to predict drug efficacy and optimize clinical development, an approach meeting the strong expectations from pharmaceutical companies for faster and more efficient development, and benefiting from increased endorsement from health ...
more
09.01.2020 – 09:03
Technische Universität München
Gene network helps to turn white fat into beneficial calorie burning fat
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/ High resolution images: https://mediatum.ub.tum.de/1524726 NEWS RELEASE A new approach to treating overweight and obesity Gene network helps to turn white fat into beneficial calorie ...
more
04.12.2019 – 12:22
APR Applied Pharma Research s.a.
FDA Grants Orphan Drug Designation to APR Applied Pharma Research's Investigational Drug for the Treatment of Epidermolysis Bullosa
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa ("APR"), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of ...
more
25.10.2019 – 10:03
Helmholtz Zentrum München
Helmholtz Zentrum München allies with Eli Lilly and Company to discover new targets for pancreatic beta cell regeneration in the treatment of diabetes
more
14.10.2019 – 17:27
Helmholtz Zentrum München
Discovery of potential novel therapeutic target for non-alcoholic fatty liver disease
more
11.06.2019 – 12:00
APR Applied Pharma Research s.a.
29th EWMA Conference: Latest Clinical Data on Nexodyn® AOS Demonstrating Higher Healing Performance in Chronic Leg Ulcers Presented by Applied Pharma Research
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa (APR) presented at the recent 29th conference of the European Wound Management Association (EWMA) in Göteborg, the results of a clinical study confirming Nexodyn® AcidOxidizing Solution (AOS) to promote the restart of the healing process in ...
more
02.05.2019 – 14:08
Helmholtz Zentrum München
Pluripotency or differentiation - that is the question
more
02.04.2019 – 15:29
OPTIMA packaging group GmbH
6
Charité and OPTIMA are developing a production machine for cell and gene therapeutics
more
One document
25.10.2018 – 13:34
Helmholtz Zentrum München
Two-pronged approach - Novel combined therapy tackles excess fatty tissue
A new combined therapy for obesity and diabetes has been shown to suppress the appetite and at the same time increase energy expenditure. Scientists from the Helmholtz Zentrum München and the Technical University of Munich (TUM), partner institutions of the German Center for Diabetes Research (DZD), have reported their findings in 'Nature Communications'. "Obesity is ...
more
09.10.2018 – 10:15
Helmholtz Zentrum München
Satiety in 3D
Many overweight people lack the feeling of being full. It was long thought that this was due to the disrupted transport of the satiety hormone leptin to the brain. That is not the case, as a group of scientists from Helmholtz Zentrum München has now shown in the 'International Journal of Obesity'. The work was made possible by a new 3D imaging technique that allows tracking the path of the hormone in the brain as shown in the video image enclosed. Leptin is an important ...
more
13.06.2011 – 14:32
Astellas Pharma Europe Limited
Interim Data From Phase 2 Trial of AC220 Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With FLT3-ITD Activating Mutations
London (ots/PRNewswire) - Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor. The study is evaluating AC220 as an oral, once-a-day, monotherapy treatment in acute myeloid ...
more

1